Article Text

Download PDFPDF
Randomised controlled trial
Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests JMF has received grants or research support from Daiichi Sankyo, Novartis and NIH and is a consultant or on a steering committee for Novartis, NIH, Daiichi Sankyo, Boehringer Ingleheim. He is also on the speakers bureau for Novartis, Daiichi Sankyo, Boehringer Ingleheim. SAN and PDL have no conflicting interests.